Crohn's disease associated with spondyloarthropathy: Effect of TNF-α blockade with infliximab on articular symptoms

Lancet

Volumn 356, Issue 9244, 2000, Pages 1821-1822

  Van Den Bosch, Filip ^a   Kruithof, Elli ^a   De Vos, Martine ^a   De Keyser, Filip ^a   Mielants, Herman ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA;

ARTHRITIS; ARTICLE; CROHN DISEASE; DISEASE ASSOCIATION; DRUG MECHANISM; HUMAN; PRIORITY JOURNAL; REMISSION; SPONDYLOARTHROPATHY; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 0034715977     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)03239-6     Document Type: Article

References (5)

1. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody
2. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group
3. Infliximab for the treatment of fistulas m patients with Crohn's disease
4. The evolution of spondyloarthopathies in relation to gut histology III: Relation between gut and joint
5. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy